Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia

BACKGROUND: Chimeric antigen receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory hematological tumors, showing impressive complete remission rates. However, around 50% of the patients relapse before 1-year post-treatment. T-cell ‘fitness’ is critical to prolong CAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Martínez, Diego, Tirado, Néstor, Mensurado, Sofia, Martínez-Moreno, Alba, Romecín, Paola, Gutiérrez Agüera, Francisco, Correia, Daniel V, Silva-Santos, Bruno, Menéndez, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516293/
https://www.ncbi.nlm.nih.gov/pubmed/36162920
http://dx.doi.org/10.1136/jitc-2022-005400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516293/
https://www.ncbi.nlm.nih.gov/pubmed/36162920
http://dx.doi.org/10.1136/jitc-2022-005400

Ejemplares similares